<SEC-DOCUMENT>0001193125-21-023650.txt : 20210305
<SEC-HEADER>0001193125-21-023650.hdr.sgml : 20210305
<ACCEPTANCE-DATETIME>20210201070151
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001193125-21-023650
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20210201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Terns Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001831363
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		650-525-5535 EXT.101

	MAIL ADDRESS:	
		STREET 1:		1065 EAST HILLSDALE BLVD., SUITE 100
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>CORRESP</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g56372g0131132659039.jpg" ALT="LOGO">
 </P> <P ALIGN="right">


<IMG SRC="g56372g45g73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">February&nbsp;1, 2021 </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I>VIA EDGAR </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">United
States Securities and Exchange Commission </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Division of Corporation Finance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Office of Life Sciences </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">100 F
Street, N.E. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Washington, D.C. 20549-6010 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Attention:&nbsp;&nbsp;&nbsp;&nbsp;David&nbsp;Burton</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"></P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Sasha Parikh </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Chris Edwards </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Celeste Murphy </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Terns Pharmaceuticals, Inc.</B> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT></B> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>Filed January</B><B></B><B>&nbsp;15, 2021</B> </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>File No.</B><B></B><B><FONT STYLE="white-space:nowrap">&nbsp;333-252180</FONT></B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Ladies and Gentlemen: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Terns Pharmaceuticals, Inc. (the &#147;<B><I>Company</I></B>&#148;) confidentially submitted a draft of the above-referenced
Registration Statement (the &#147;<B><I>Registration Statement</I></B>&#148;) to the Commission on November&nbsp;10, 2020, resubmitted to the Commission on December&nbsp;15, 2020, and subsequently filed the Registration Statement with the Commission
on January&nbsp;15, 2021. The Company is providing this letter in response to the comment letter to the Registration Statement received on January&nbsp;29, 2021 from the staff of the Commission (the &#147;<B><I>Staff</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">For ease of review, we have set forth below the numbered comment of the Staff&#146;s letter in bold type followed by the
Company&#146;s response thereto. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>February 1, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>Page 2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g56372g0108070825652.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><U>Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations
</U></I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><U>Critical accounting policies and significant judgments and estimates </U></I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><U>Common stock valuation methodology, page 105 </U></I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>In your response dated January&nbsp;26, 2021, you noted that in October 2020 you reassessed the grant
date fair value of all your grants made during the nine month period ended September&nbsp;30, 2020. Your response does not address how you assessed the impact of the revaluation on your previously issued financial statements. If true, please revise
your disclosure to confirm that you determined that the incremental stock compensation applicable to the historical quarterly periods was immaterial to those respective periods. In addition, revise your disclosure to quantify the aggregate number of
options granted that were impacted by the retrospective valuation of your common stock as of September&nbsp;1, 2020, the aggregate stock compensation to be recorded in the three month period ended December&nbsp;31, 2020, and the incremental
additional stock compensation expense that will be recorded in the three month period ended December&nbsp;31, 2020 as a result of this retrospective valuation. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Response</I>:&nbsp;&nbsp;&nbsp;&nbsp;The Company respectfully acknowledges the Staff&#146;s comment. In furtherance of the
discussion with Ms.&nbsp;Parikh of the Staff on Friday, January&nbsp;29, 2021, the Company submits this response in order to clarify its supplemental response of January&nbsp;26, 2021 responding to the Staff&#146;s Comment #8 of its letter dated
December&nbsp;7, 2020. The Company respectfully advises the Staff that the aggregate stock compensation expense recorded for the nine months ended September&nbsp;30, 2020 reflects the grant date fair value for option awards granted during such
period utilizing the retrospective valuations received in October 2020 (e.g., there is no incremental stock compensation expense applicable to the historical quarterly periods). For further clarity, in light of the foregoing, the Company confirms
that no additional stock compensation expense as a result of the reassessed value will be recorded in the Company&#146;s operating expenses in the financial statements covering the three months ended December&nbsp;31, 2020. The Company has revised
page&nbsp;106 of the Registration Statement to further clarify that the aggregate stock compensation expense for the nine months ended September&nbsp;30, 2020 reflects the reassessed grant date fair value from the retrospective valuations received
in October 2020. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><U>Notes to Unaudited Condensed Consolidated Financial Statements </U></I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B><I><U>14. Subsequent Events, page <FONT STYLE="white-space:nowrap">F-57</FONT> </U></I></B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify"><B>We note that the December 2020 option grant appears to be included in disclosure provided in Item 15.
Recent Sales of Unregistered Securities: Equity Plan-Related Issuances on <FONT STYLE="white-space:nowrap">page&nbsp;II-2.</FONT> Further, you state in your response dated January&nbsp;26, 2021 that you anticipate using the initial public offering
price as the grant date fair value for your grant of options in December 2020. Please revise Note&nbsp;14 to disclose all of the relevant information regarding your grant of options in December 2020, including how you intend to value these options.
</B></P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>Response</I>:&nbsp;&nbsp;&nbsp;&nbsp;The Company respectfully acknowledges the Staff&#146;s
comment and has revised page&nbsp;F-58 of the Registration Statement to provide the material information related to the stock options granted on December&nbsp;30, 2020, including the aggregate number of shares exercisable underlying the stock option
grants, the vesting period for such grants, the exercise price of the stock option awards and the Company&#146;s intention to utilize the price to the public for purposes of the grant date fair value for recording stock compensation expense for the
three months ended December&nbsp;31, 2020 in light of the proximity of the grants to the Company&#146;s IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">* * * </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>February 1, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="justify"><B>Page 3 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="justify">


<IMG SRC="g56372g0108070825652.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify">We hope the foregoing answers are responsive to your comments. Please do not hesitate to
contact me by telephone at (650) <FONT STYLE="white-space:nowrap">463-</FONT> 3014 or by fax at (650) <FONT STYLE="white-space:nowrap">463-2600</FONT> with any questions or comments regarding this correspondence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Very truly yours, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">/s/ Brian Cuneo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Brian J. Cuneo, Esq. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:55%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">of LATHAM&nbsp;&amp; WATKINS LLP </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">cc:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Senthil Sundaram, Terns Pharmaceuticals, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Bryan Yoon, Esq., Terns Pharmaceuticals, Inc. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Nathan Ajiashvili, Esq., Latham&nbsp;&amp; Watkins LLP </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Michael Podolny, Esq., Latham&nbsp;&amp; Watkins LLP </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Yasin Keshvargar, Esq., Davis Polk&nbsp;&amp; Wardwell LLP </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="justify">Alan F. Denenberg, Esq., Davis Polk&nbsp;&amp; Wardwell LLP </P></TD></TR></TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g56372g0108070825652.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g56372g0108070825652.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  , *(# 2(  A$! Q$!_\0
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K?0YB37/%RR,(O#Z2Q@D)(3LWCL=I;*Y]#THKL:*KE?<Q]O'^1?C_ )G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g56372g0131132659039.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g56372g0131132659039.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  1 .T# 2(  A$! Q$!_\0
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MOS!IT\<<&VZ8$ @YR>_2NS^%^KMJO@BUCF)^TV+&TF!/(*=,_P# <52\#_\
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HJ?XE^IY;H/\ R65_^OQ__0J^B***C#;/U.O.?CI_X4%%%%=!XQ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g56372g45g73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g56372g45g73.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MRX;>9Y?-$6Q7C;DJS9R'(X"GOF@"?1-5&K6"7"H0=JAV PI?'S <YX/'/ZT
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M]<^M $<MA9S(R2VD,B-C<K1@@XZ9^E "_8K4S),;:'S438K[!N5?0'L.3Q0
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MS0!TR,616(VDC./2@!U !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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MT"_SR .C\-W*:I%.9HA;QSL0@)SY>[>@Z=0Q/X4 =+0 4 % !0 4 % !0 4
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MRL[X^=IW++@Y^5LY7J>F* $?1;*16#"?YP Y^TR N ,88[N?QH OJH50J@
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M%>3>&91F%P&*YW!21AB,'@9Z4 758.BL,@$9&1@_D: %H * "@ H * "@ H
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MXQS0!-:Z=:V3;H(R&VE=S.S$@L6.22<\DG/O0!:H * "@ H * "@ H * "@
MH * "@ H S]7NIK.W@>!69FN(T*KC+ GD#/% &<->NHS<AK3+I)(PCED5"D:
M(A(RNX$_-Q_,8H 4^)B/,<V8$7SB(^;RS+M^\,?*/F'.30!+<:M<G0[ZY$8@
MN+:0QX1O,&01G&0,]?2@!@UBZCCWM&LEQ*[C[.[A%@" D@L 221@^ASQQR0
M?Q(5WRBSS;!3M8R8<GR1+RN, 8.,YH TM/O);O[0L\"0R02^6P23>#\JMD'
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M-/I]E<[O/M()=Y!;?&&SC.,Y],G\Z "XL;>YBEC>-09 074 ,"5VD@^N.,T
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MZNH)$$!V)&@D<G="5;)9..21QVZ"@#+DT"\LK$(C(]S)*HCF1"S)NRK*3CA
MI+ ^OOC(!IVFAR6FK).BPB&-B5D!/F%-@41D8QM&,]>PXH W: "@ H * "@
MH * "@ H * "@ H * ,_6-3&DV:W)B\U?,"D!L8!ZG\!VH BCUR%[N\B,<AC
MMV15>-&D+D@YPJ@G@J1^% "3^(;*-K81,91,5Y"L JL"02<8S@?=ZT *?$%D
M%9P[%-JL@$;[FR&/W=O3"DYYXYX[@%ZSN/M=C;W.W9YL:OMSG&1G% $] !0
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M.@!H\/Z8,_N&(((VF9R!GK@9P,^U %Z&WBM_,\I=OF.7;DG+'J: ): "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
C "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
